NEW YORK – About 10 percent of the nearly 70 patients who received Bluebird Bio's gene therapy for cerebral ...
Seven of 67 patients who received the cerebral adrenoleukodystrophy gene therapy developed blood cancer, though most cases ...
NEW YORK – Following positive data from a Phase Ib clinical trial, Immatics is moving its T-cell receptor (TCR) therapy ...
The firm plans to use the proceeds to advance its pipeline of T-cell receptor therapies and support their manufacturing, production, and commercialization.
In a post hoc analysis within a prior Phase II study, the company found SP-624 improved symptoms in female patients with major depressive disorder.
AstraZeneca Advancing Plan to Launch Biomarker-Driven Drugs as Alternative to Chemo in Breast Cancer
The drugmaker wants to establish Enhertu in HER2-ultralow breast cancer and even HER2-negative tumors but remains committed to precision medicine strategies.
In the INAVO120 trial, Itovebi added to Pfizer's Ibrance and fulvestrant doubled progression-free survival versus Ibrance and fulvestrant alone.
Researchers will develop therapies for urea cycle disorders and create a platform to rapidly develop treatments for other rare genetic disorders.
The firm will use the court-administered restructuring process to pursue strategic alternatives so it can continue developing vaccines and immunotherapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback